Amyotrophic Lateral Sclerosis (ALS) Advanced Treatment Access & Specialist Care

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects the motor neurons responsible for controlling voluntary movement. Upper motor neurons in the brain and lower motor neurons in the spinal cord and brain stem are selectively destroyed over time, leading to progressive muscle weakness, wasting, and eventually respiratory failure. Most ALS cases are sporadic (no family history), but around 10% are familial, caused by heritable genetic mutations — most commonly a C9orf72 repeat expansion or a mutation in SOD1, FUS, or TARDBP. The exact triggers for motor neuron degeneration are not fully understood and are under active investigation.

Yes — genetic testing is now recommended for all patients with ALS, regardless of whether there is a family history. This is because approximately 1 in 10 apparently sporadic ALS patients carries a causative germline mutation. Identifying the mutation has direct implications: it determines eligibility for targeted therapies (such as tofersen for SOD1-ALS), informs clinical trial eligibility, allows risk assessment and counselling for family members, and may provide prognostic information. Comprehensive multigene panel testing covering C9orf72, SOD1, FUS, TARDBP, and other ALS-associated genes is recommended at a specialist genetics service.

Tofersen (brand name Qalsody) is an antisense oligonucleotide (ASO) — a strand of synthetic nucleic acid — that targets SOD1 mRNA in motor neurons. By causing degradation of the SOD1 mRNA, it reduces production of the mutant SOD1 protein that causes motor neuron death in SOD1-mutant ALS. It is administered by intrathecal injection (into the spinal fluid) at specialist centres. Tofersen received accelerated FDA approval in 2023 for adult patients with ALS who have a confirmed pathogenic SOD1 variant. It reduces plasma neurofilament light chain (NfL) — a biomarker of neuroaxonal injury — and is the first gene-specific approved treatment in ALS.

These are three approved disease-modifying treatments for ALS that work through different mechanisms. Riluzole (oral tablet, twice daily) reduces glutamate-mediated excitotoxicity and is the oldest and most widely available ALS treatment; it modestly extends median survival. Edaravone (intravenous, or oral suspension in some countries) is a free-radical scavenger that reduces oxidative stress; it was found to slow ALSFRS-R decline in a specific subgroup of patients with relatively early disease and rapid rate of decline. AMX0035 (sodium phenylbutyrate + taurursodiol, brand name Relyvrio) targets endoplasmic reticulum stress and mitochondrial dysfunction and was approved in North America in 2022/2023; availability varies by country. These treatments are not alternatives to each other — they may be used in combination.

ALS clinical trials evaluate new treatments — including gene-targeting antisense oligonucleotides (ASOs) for C9orf72, FUS, and TDP-43; neuroprotective agents; and cell-based therapies — in patients with ALS. Eligibility depends on genetic subtype, disease stage, rate of progression, respiratory function, and other factors. Specialist ALS research centres are the primary enrolment sites. CancerFax can assist patients in identifying open trials matching their genetic profile and clinical stage — including programmes at centres in India, China, the US, and Europe — and in facilitating initial contact and eligibility pre-screening.

ALS progression varies considerably between individuals. Median survival from symptom onset is 2–4 years, but a meaningful proportion of patients survive 5–10 years or longer. The rate of ALSFRS-R decline in the first 6–12 months from onset is the strongest individual predictor of overall survival trajectory. Bulbar-onset disease, older age, and elevated plasma NfL at diagnosis tend to be associated with faster progression; limb-onset disease in younger patients with slow initial decline may follow a longer course. Prognosis should always be discussed individually with a specialist ALS team rather than based on population averages alone.

Frontotemporal dementia (FTD) and ALS lie on a clinical spectrum, and approximately 10–15% of ALS patients develop concurrent FTD — characterised by prominent behavioural disinhibition, personality change, and executive dysfunction rather than memory loss. The C9orf72 hexanucleotide repeat expansion is the most common cause of both familial ALS and familial FTD, and strongly predisposes to the combined ALS-FTD syndrome. Identifying cognitive and behavioural changes early is important because they affect decision-making capacity, advance care planning, and carer support needs.

Non-invasive ventilation (NIV — typically BiPAP) should be initiated when forced vital capacity (FVC) falls below 50% predicted, when sniff nasal inspiratory pressure (SNIP) is markedly reduced, or when symptoms of nocturnal hypoventilation develop — such as morning headaches, excessive daytime sleepiness, orthopnoea, or disturbed sleep. Early NIV initiation, before respiratory failure becomes acute, is associated with improved quality of life and extends median survival by several months. NIV tolerance varies; early introduction allows gradual acclimatisation. Respiratory function should be assessed every 3 months at an ALS multidisciplinary clinic.

Yes. CancerFax supports ALS patients and families by reviewing neurological assessments, functional rating scales, and genetic panel results; identifying eligibility for approved targeted therapies including tofersen for SOD1-ALS; coordinating second opinions with specialist ALS multidisciplinary centres; and facilitating access to clinical trial programmes and novel therapy pathways in India, China, and internationally. Please share your medical records through the CancerFax portal or contact our team to begin the process.